Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
$3.41
-$0.19(-5.85%)
At close: 4:00 PM EST
$3.41
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$1.54 - $4.09
Previous CloseN/A
Volume977.37K
Average Volume (3M)7.60M
Market Cap
$1.25B
Enterprise Value$260.10M
Total Cash (Recent Filing)$607.72M
Total Debt (Recent Filing)$203.37M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 05, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding342,272,740
10 Day Avg. Volume6,312,115
30 Day Avg. Volume7,600,994
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.21
Enterprise Value/Revenue18.12
Enterprise Value/Gross Profit65.78
Enterprise Value/Ebitda-1.25
Forecast
1Y Price Target
$9.60Price Target Upside181.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market PositioningNuvation Bio's engagement with a high percentage of tier one and tier two target accounts and the inclusion of Ibtrozi in NCCN guidelines as a Preferred Agent for ROS1+ NSCLC signal strong market positioning.
Regulatory ApprovalIBTROZI now approved in Japan; milestone payment anticipated imminently upon establishment of reimbursement.
Revenue GrowthLead asset Ibtrozi has full FDA approval for ROS1+ NSCLC with a broad line-agnostic label, which could drive significant revenue.
Bears Say
Clinical Data RisksRisks include negative clinical proof-of-concept data for any of the company's drug-drug conjugate candidates or other pipeline programs.
Market CompetitionPoorer-than-anticipated commercial uptake of company products, particularly taletrectinib, due to higher-than-anticipated levels of competition or other market-related factors.
Market SizeBear case highlights niche market and competitive threats with the ROS1 NSCLC being approximately 3K patients in the U.S.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.54 and its highest was $4.09 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $1.25B.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Nov 05, 2025 which is in 18 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Aug 07, 2025. The company reported -$0.17 earnings per share for the quarter, the consensus estimate of -$0.17 by $0.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.17.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 342,272,740 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.17 in its last earnings report, expectations of -$0.17. Following the earnings report the stock price went down -0.426%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.60 (181.52% Upside)
$9.60 (181.52% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.24%
12-Months-Change
Fundamentals
Return on Equity
-64.40%
Trailing 12-Months
Asset Growth
8.81%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio (NUVB) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company operates within the pharmaceutical and biotechnology sectors and is dedicated to advancing a proprietary pipeline of novel oncology drug candidates. Nuvation Bio aims to address unmet medical needs by targeting multiple tumor types with its differentiated therapeutic approaches.
NUVB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant progress towards the potential approval and launch of taletrectinib, underpinned by strong clinical data and a solid financial position. However, there are concerns about the increased net loss and potential challenges in achieving rapid market penetration.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$9.60
▲(181.52% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
19.41% Insiders
15.99% Mutual Funds
0.03% Other Institutional Investors
55.49% Public Companies and Individual Investors